156 results about "Oil adjuvant" patented technology

The present invention belong to veterinary new biological medicine technology field, relates to porcine circovirus type II (PCV2) inactivated vaccine of and method for preparing same. The vaccine used seed virus is porcine circovirus type II DBN-SX07 strain, the preservation number is CGMCC No 3064, the virus strain is used as antigen preparation of inactivation by alkyl agents and emulsification by adding oil adjuvant. Using the invention provided PCV2 inactivated vaccine to immune pig can generate an uniform and effective protection force-shorting PCV2 infection windows period obviously, and prolong immune duration-reducing times of booster immunization.

The invention provides a method for preparing triple vaccine for preventing porcine transmissible gastroenteritis, porcine epidemic diarrhea and porcine rotavirus. The method comprises the following steps: inoculating a host-cell line with a 90 percent grown monostratum against a porcine transmissible gastroenteritis virus, a porcine epidemic diarrhea virus and a porcine rotavirus respectively, and adding a cell maintenance media into the host-cell lines respectively to be cultured at 37 DEG C; after cytopathic effect reaches over 75 percent, collecting viruses to be stored at 20 DEG C below zero for standby; mixing the viruses according to 10 TCID50 in 1:1:1, and simultaneously adding Freund's complete adjuvant and immunopotentiator into the mixture to inactivate the mixture by formaldehyde at 37 DEG C for 24 hours; and adding an oil adjuvant into the mixture to prepare a vaccine of water-oil-water preparation. The method can be used for preparing the triple vaccine for preventing the porcine transmissible gastroenteritis, the porcine epidemic diarrhea and the porcine rotavirus so as to solve the problem that the diseases do not have an effective medicine to treat currently.

The invention discloses a water-in-oil-in-water adjuvant vaccine and a preparation method thereof. The adjuvant vaccine is composed of an internal water phase, a middle oil phase used for cladding the internal water phase, and an external water phase for cladding the middle oil phase. The external water phase comprises: a composite surfactant, a hydrophilic surfactant and mormal saline. The middle oil phase consists of: a lipophilic surfactant, a stabilizer and mineral oil. The internal water phase comprises: an immunopotentiator solution, the hydrophilic surfactant, and an inactivated antigen solution. The W/O/W (water-in-oil-in-water) type adjuvant vaccine provided in the invention can induce an immunoreaction earlier than traditional W/O (water-in-oil) type adjuvant vaccines, and can make experimental animals obtain earlier protective antibodies. The vaccine has good absorption, and causes a small inflammatory response at an inoculation site. The adjuvant vaccine disclosed in the invention has better stability than existing W/O/W type vaccines, and the antibody generation speed is fast.

The invention discloses rhodococcus ruber and application of same as an immunologic adjuvant in preparing vaccine. The rhodococcus ruber is also called rhodococcus ruber RDC-01, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO. 16640. The rhodococcus ruber disclosed by the invention has the function of increasing and regulating the body immunity andis capable of nonspecifically enhancing the activity of TB (Tuberculosis) lymphocyte, macrophagocyte and NK cells and inducing multiple cell factors such as interferon, and the rhodococcus ruber canbe used as the immunologic adjuvant after being inactivated so as to be added in an oil-adjuvant inactive vaccine, so that generation of an animal antibody induced by the vaccine can be obviously promoted; compared with single use of the oil-adjuvant inactive vaccine, a high-titre antibody can be generated, the use is safe, long-term and short-term toxic and side effects are not generated, and anapplication prospect in the field of preparation of vaccines for animals is good.

The invention discloses a foot-and-mouth disease genetic engineering mixed epitope vaccine and a preparation method thereof. The vaccine consists of the following four parts: a serial B cell epitope recombinant protein BI consisting of main neutralizing epitops of O-type foot-and-mouth disease viruses in Cathay, Transasia and Mya 98 pedigrees with a gene sequence of SEQ ID NO:1 and an amino acid sequence of SEQ ID NO:2, a T-cell epitope recombinant protein TI consisting of serial connection of universal T-cell epitope and a plurality of foot-and-mouth disease virus specific T-cell epitopes with a gene sequence of SEQ ID NO:3 and an amino acid sequence of SEQ ID NO:4, Toll-like receptor 3 agonist-polyinosinic acid-polycytidysic acid and/or Toll-like receptor7/8 agonist-R848 serving as immunopotentiator, and 201 oil adjuvant. When being used for immunizing a pig, the BI and TI mixed epitope vaccine prepared by utilizing the method can produce a protective immunization effect the same as or better than that of an inactivated influenza virus Vaccines, and has a cross protection effect to viruses of the three pedigrees, so that the vaccine is a novel immune-enhanced O-type foot-and-mouth genetic engineering mixed epitope vaccine.

The invention aims at providing a new castle disease and H9 subtype bird flu bivalent vaccine. The new castle disease and H9 subtype bird flu bivalent vaccine contains antigens and adjuvant. The antigens are inactivated H9 subtype bird flu viruses and new castle disease viruses. The H9 subtype bird flu viruses are QDY strains, and the preservation number of the H9 subtype bird flu viruses is CCTCC v201517. The QDY strains of the H9 subtype bird flu viruses and a Lasota strain of the new castle disease viruses are inoculated to chick embryos respectively, and then virus liquid is collected; the virus liquid and the oil adjuvant are mixed and emulsified into the vaccine after the virus liquid is inactivated through a formaldehyde solution. The new castle disease and bird flu bivalent inactivated vaccine is good in immunogenicity, antibody production is fast after immunity, the produced antibody titer is high, the produced antibody holding time is long, the retention period is long, the immunizing dose is small, the selected adjuvant is easy to inject, and two kinds of diseases can be prevented through one-time injection. The vaccine has the advantages of being efficient and good in safety.

The present invention relates to stable emulsifiable concentrates comprising an oil adjuvant and at least one member selected from the group consisting of herbicidally active 2-[4[(5-chloro-3-fluoropyridin-2-yloxy)-phenoxy]-propionic acid derivatives and quinoline derivative safeners and to the use thereof as a pesticide.

The invention relates to a bacterium for the production of genetically-engineered subunit oil-adjuvant vaccines against infectious bursal disease, i.e. Escherichia coli BL21/pET-28a-VP2, CCTCC No: M204038. The process for constructing the bacterium consists of inserting VP2 protein gene of the infectious bursal disease virus onto expression plasmid pET-28a to construct prokaryotic expression plasmid, then using the prokaryotic expression plasmid to transform the escherichia coli BL21, using lactose as inducer to induce Escherichia coli BL21/pET-28a-VP2 expression VP2 protein, purifying and charging oil-adjuvant to obtain the vaccines.

The invention aims at providing an H9 subtype avian influenza virus strain. Vaccine is prepared by the virus strain to solve the problem that existing H9 subtype avian influenza virus vaccine is poor in immune effect caused by a novel virus. The H9 subtype avian influenza virus QDY strain (Avian Influenza Virus) is preserved in the typical culture preservation center in China in Wuhan University on April 29, 2015, and the preservation number is CCTCC NO: V201517. After the H9 subtype avian influenza virus (QDY strain) is inoculated to a chick embryo, a virus solution is collected, after ultrafiltration concentration and formaldehyde solution inactivation are performed, oil adjuvant is added, and then mixing and emulsifying are performed to prepare the vaccine. According to the prepared vaccine, the antibody level after immunization can be improved, the antibody uniformity after immunization can be improved, and the immune effect of the vaccine can be guaranteed; the vaccine has the advantages of being efficient and good in safety.

The invention discloses a ginsenoside-containing vegetable oil adjuvant and a preparation method and application thereof. The ginsenoside-containing vegetable oil adjuvant is characterized in that edible vegetable oil is used as the adjuvant oil; the ginsenoside-containing vegetable oil adjuvant comprises 10 to 100mu g/mL ginsenoside. According to the preparation method, the ginsenoside-containing vegetable oil is utilized for preparing vaccines, so that the vaccine safety can be greatly improved, and the potential hazard of the general mineral oil adjuvant on food hygiene is avoided; after being mixed, ginsenoside and vegetable oil play the effect of collaborating with the adjuvant, thus the valence of antibody is raised by 4.7 times, and the antibody level of the vaccines is also greatly improved; in addition, the prepared vaccine is high in mobility, convenient for inoculation, small in local stimulation, and thus relieving pain on animals; when the ginsenoside-containing vegetable oil adjuvant is applied to vaccine production, the existing production process is remained, and the method is simple and convenient.

The invention discloses a porcine parvovirus L strain and use thereof in preparation of porcine parvovirus inactivated vaccines. In the invention, microbial preservation number of the separated strain is CGMCC No. 3352. The strain is highly homologous with an NADL-2 strain and a China strain and keeps high reproduction, and the viruses are stable. Oil adjuvant is added into antigen liquid which inactivates the viruses by using binary ethylenimine to prepare the bidirectional oil-emulsion inactivated vaccines; and the prepared inactivated vaccines are applied in a vaccine inoculation experiment of 10,276 pigs (most of which are first farrowing sows), and in the experiment, an immune dosage of 2 millimeters is given to each pig through muscle injection, and each time of inactivated vaccine inoculation can obtain an immune period of over 6 months. Under the conditions that a 10 millimeter overdose vaccine is injected into a pig and that single dose inoculation is repeatedly carried out for three times, no abnormal reaction happens, which proves that the inactivated vaccines have high immunogenicity and safety.

The invention discloses a Newcastle disease-H9 subtype avian influenza bivalent dual-adjuvant inactivated vaccine and a preparation method thereof. The bivalent vaccine consists of a concentrated and inactivated ND and AI (H9) venom, levamisole hydrochloride and an oil adjuvant, wherein every milliliter of inactivated vaccine contains 0.5-16 mg of levamisole hydrochloride immunopotentiator. When the synergic ND-AI (H9) bivalent dual-adjuvant inactivated vaccine prepared with the method is applied to immunized chicken, the humoral immunity and cell immune levels of table poultry and laying hens can be raised effectively, the growth is promoted, and rate of live weight growth is increased. The bivalent dual-adjuvant inactivated vaccine has an immune effect which is remarkably superior to that of the conventional chicken ND-AI bivalent oil emulsion inactivated vaccine, and can be used for effectively protecting chicken flocks from being intruded by the ND virus and AI (H9) virus and preventing the Newcastle disease and H9 subtype avian influenza at the immune period.

The present invention provides a W/O/W type oil adjuvant vaccine containing an outer aqueous phase containing 0.5 wt %-20 wt % of a polyethylene glycol derivative having a molecular weight of 400-20,000, and an inner aqueous phase containing a biologically acceptable and effective amount of an antigen. The constitution of the present invention that a polyethylene glycol derivative having a specific molecular weight is contained in the outer aqueous phase enables preparation of a W/O/W type oil adjuvant vaccine showing a high adjuvant effect, reduced side effects such as topical response, superior preparation stability and superior workability to allow a person to give an injection easily due to the lowered viscosity.

The invention relates to an oil adjuvant of inactivated vaccine. The oil adjuvant consists of white oil for injection and mannitol olein which are mixed in volume proportion of 90:10 to 100:8. The oil adjuvant of the inactivated vaccine has the advantages that: 1) the oil adjuvant of the inactivated vaccine is convenient for use, the process for manufacturing the inactivated vaccine is simplified, the inactivated vaccine is manufactured by one step in stead of three steps at present, and the cost of the vaccine is reduced; 2) the oil adjuvant of the inactivated vaccine is almost nontoxic, the content of aromatic hydrocarbon of the white oil used in the invention is low and is less than 50ppm, after the vaccine is injected into an animal body, the vaccine causes very small erythema and does not influence the quality and the appearance of meat; and 3) the oil adjuvant of the inactivated vaccine has low viscosity coefficient, has low resistance for pushing a pin when being used for animal epidemic prevention injection and is convenient for injecting.

The invention discloses bovine capsular serotype A Pasteurella mutocida and application thereof. The bovine capsular serotype A Pasteurella mutocida is separated from disease samples with haemorrhagic septicomia of cattle in six provinces (cities) with the microbial preservation number of CGMCC No.3619. The bovine capsular serotype A Pasteurella mutocida is cultured by BHI, oil adjuvant is adopted to prepare inactivated immunogen, and a mouse model proves that the bovine capsular serotype A Pasteurella mutocida has complete protecting function on serotype A Pm velogenic attck, and does not have crossing protection with serotype B Pm. Testing results prove that vaccine can be prepared by the bovine capsular serotype A Pasteurella mutocida for preventing the haemorrhagic septicomia of cattle caused by the capsular serotype A Pasteurella mutocida. The strain cannot cause diseases when inoculated to chicks, which proves that the strain is chicken isolated capsular serotype A Pasteurella mutocida.

The invention provides a Muscovy duck parvovirus inactivation vaccine which comprises an antigen and a vaccine adjuvant, wherein the antigen is inactivated Muscovy duck parvovirus, and the collection number of the Muscovy duck parvovirus is CGMCC No.8504. The Muscovy duck parvovirus inactivation vaccine provided by the invention is prepared by the steps of screening a Muscovy duck parvovirus YBMDP strain with low toxicity and high immunogenicity; inoculating and collecting the virus liquid; performing ultrafiltration concentration and formaldehyde solution inactivation; adding an oil adjuvant and mixing and emulsifying to obtain the vaccine. The vaccine provided by the invention can improve the antibody level of Muscovy duck, guarantee the maternal antibody level of the filial generation and prevent the duckling parvovirus infection caused by the Muscovy duck parvovirus; the vaccine has the advantages of high efficiency and good safety.

The invention relates to an inactivated vaccine of cow chlamydia, its preparation and the related inspection method during the vaccine preparation. The preparing process comprises diluting the Chlamydia psittaci SX 5 or NX with microcosmic salt buffering liquid or physiological saline, vaccinating to healthy chick embryo hatched at 37 deg. C for 6-7 days, harvesting vitelline membrane and allantois liquid of dead chick embryo after 72 hours as antigens, triturating the antigens, diluting and charging formaldehyde for deactivation, mixing the deactivated antigens with oil adjuvant by the proportion of 1:1, stirring homogeneously, carrying out homogeneous emulsion to obtain the vaccine.

The present invention relates to an avian influenza H9 subtype inactivated vaccine, which is formed by mixing two strains of inactivated H9 subtype avian influenza viruses and an oil adjuvant, wherein the two strains of the inactivated H9 subtype avian influenza viruses are respectively the HZ strain and the FJ strain, the HA gene sequence of the HZ strain is represented by SEQ ID NO:1, and the HA gene sequence of the FJ strain is represented by SEQ ID NO:2. According to the preparation method, the virus solution of the HZ strain and the virus solution of the FJ strain of the H9 subtype avian influenza viruses are prepared and inactivated, the oil phase solution and the water phase solution are prepared, and emulsification is performed to obtain the finished product. According to the present invention, the two strains of the H9 subtype avian influenza viruses separated from different places are utilized to prepare the inactivated vaccine with characteristics of strong immunogenicity and good cross-protection property, wherein the inactivated vaccine can be used for prevention of chicken H9 subtype avian influenza diseases. In addition, after the inactivated vaccine is adopted to immunize chicken, the antibody titer is high so as to make the chicken have good virus challenge protection property on the H9 subtype strains epidemic in different places, the safety is high, and the efficacy is stable.

The invention discloses a quadruple inactivated vaccine for preventing chicken diseases, which is prepared by respectively vaccinating Newcastle disease virus ZM10 strain, infectious bronchitis virus M41 strain and H9 subtype avian influenza virus S2 strain in a susceptible chicken embryo, and collecting an infected chicken embryo solution; vaccinating egg drop syndrome virus AV-127 strain in a susceptible duck embryo, and collecting an infected duck embryo solution; and concentrating the collected virus solutions, inactivating, blending with an oil adjuvant, and emulsifying. The quadruple vaccine provided by the invention can be used for preventing diseases caused by Newcastle disease viruses, infectious bronchitis viruses, egg drop syndrome viruses and avian influenza (H9 subtype) viruses to achieve the effect of preventing four diseases simultaneously and reduce immune cost and immune stress reaction.

The invention provides a competitive ELISA qualitative and quantitative detection method of an oil adjuvant vaccine. The method comprises the following steps of coating an antigen, diluting an antibody, diluting the antigen, drawing an antigen standard curve and quantitatively detecting the to-be-detected antigen. The method comprises the specific steps: firstly enabling the to-be-detected antigen to react with the antibody with known concentration to completely neutralizing the antibody and the antigen; and then enabling the neutralized solution to react with the antigen adsorbed in an ELISA plate in a solid-phase way to determine the concentration of the to-be-detected antigen. The standard curve slope obtained by the invention is able to be greater than that obtained through an indirect competition method, thereby greatly improving the detection sensitivity; the detection method disclosed by the invention is extensive in detection, and capable of detecting the synthetic peptide antigen finished product, semi-finished product and vaccine antigen; and an aqueous-phase sample obtained after vaccine demulsification can be determined without performing the purification treatment; the spent time is short in comparison with other detection method; and the lowest detection limit of the antigen sample according to the invention can achieve 1ng/mL-1.5ng/mL.

The invention belongs to the technical field of biological products for veterinary uses, in particular to a method for preparing a riemerella anatipestifer and escherichia coli bigeminal inactivated vaccine and a preparation method thereof. The vaccine is prepared by inoculating riemerella anatipestifer I type, riemerella anatipestifer II type and escherichia coli O78 type which have excellent immunogenicity into a culture medium for culture, using formaldehyde solution to inactivate the bacteria and emulsifying the resulting product by an oil adjuvant. The bigeminal inactivated vaccine is used for preventing and controlling infectious serositis and colibacillosis of a duck. The preparation method of the vaccine has a simple operation; and the prepared vaccine has stable performance and can effectively prevent and control the infectious serositis and the colibacillosis of the duck.

The invention particularly relates to a pig breeding and respiratory syndrome NVDC-JXA1 strain-porcine parvovirus disease duplex inactivated vaccine and a preparation method and application thereof. The pig breeding and respiratory syndrome NVDC-JXA1 strain-porcine parvovirus disease duplex inactivated vaccine is prepared by enabling pig breeding and respiratory syndrome virus NVDC-JXA1 strain to inoculate with a Marc-145 cell, enabling a porcine parvovirus virulent strain to inoculate with an ST cell, respectively obtaining infection cell culture fluid to be inactivated by using formaldehyde solution, and conducting ultrafiltration, concentration and mixing to obtain mixed virus liquid to be mixed and emulsified with oil adjuvant. The inactivated vaccine comprises, by weight, 1-2 parts of the oil adjuvant and 1 part of mixed virus liquid aqueous phase, the inactivated vaccine is prepared by preparing pig breeding and respiratory syndrome virus liquid, porcine parvovirus liquid, an oil phase, the aqueous phase and emulsifying, and NVDC-JXA1 strain pig breeding and respiratory syndrome-porcine parvovirus disease duplex inactivated vaccine quality standards are built.